TruWealth Advisors LLC grew its position in Abbott Laboratories (NYSE:ABT – Free Report) by 2.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 123,522 shares of the healthcare product maker’s stock after purchasing an additional 3,046 shares during the period. TruWealth Advisors LLC’s holdings in Abbott Laboratories were worth $14,083,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in the company. Unique Wealth Strategies LLC acquired a new stake in shares of Abbott Laboratories during the second quarter worth approximately $28,000. Redmont Wealth Advisors LLC acquired a new stake in Abbott Laboratories during the 1st quarter valued at $30,000. Future Financial Wealth Managment LLC bought a new position in Abbott Laboratories in the 3rd quarter valued at $31,000. Itau Unibanco Holding S.A. acquired a new position in Abbott Laboratories in the second quarter worth $32,000. Finally, Ridgewood Investments LLC acquired a new stake in shares of Abbott Laboratories in the second quarter valued at $37,000. Institutional investors own 75.18% of the company’s stock.
Insider Buying and Selling at Abbott Laboratories
In related news, CEO Robert B. Ford sold 141,679 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the sale, the chief executive officer now directly owns 220,059 shares in the company, valued at $25,617,068.19. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.10% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Stock Analysis on Abbott Laboratories
Abbott Laboratories Trading Up 0.1 %
ABT opened at $117.90 on Friday. Abbott Laboratories has a twelve month low of $91.64 and a twelve month high of $121.64. The firm has a market cap of $205.10 billion, a PE ratio of 36.73, a price-to-earnings-growth ratio of 2.74 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.68. The firm’s fifty day moving average is $113.76 and its two-hundred day moving average is $108.47.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.01. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $10.55 billion. During the same period in the previous year, the company posted $1.14 earnings per share. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Equities research analysts anticipate that Abbott Laboratories will post 4.66 EPS for the current year.
Abbott Laboratories Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a dividend of $0.55 per share. The ex-dividend date is Tuesday, October 15th. This represents a $2.20 annualized dividend and a yield of 1.87%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 68.54%.
Abbott Laboratories Company Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Consumer Staples Stocks, Explained
- UPS vs. FedEx: Which Stock Delivers Better Holiday Gains?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Insider Selling is not a Signal to Start Selling Gartner Stock
- How to Buy Cheap Stocks Step by Step
- Taiwan Semiconductor Soars on Earnings With More Room to Run
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.